Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer.

Song, Si Yeon; Park, Ji Hye; Park, So-Jung; Kang, In-Cheol; Yoo, Hwa-Seung

Song, Si Yeon; Park, Ji Hye; Park, So-Jung; Kang, In-Cheol; Yoo, Hwa-Seung.

Afiliación

Song SY; Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea.
Park JH; Seoul Korean Medicine Hospital of Daejeon University, Seoul, Republic of Korea.
Park SJ; Korean Medicine Hospital of Pusan National University, Yangsan-si, Republic of Korea.
Kang IC; Innopharmascreen, Inc., Incheon, Republic of Korea.
Yoo HS; Hoseo University, Asan, Republic of Korea.

Integr Cancer Ther ; 21: 15347354221144311, 2022.

Article en En | MEDLINE | ID: mdl-36565160

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Animales; Ratones; Carcinoma de Pulmón de Células no Pequeñas/patología; Afatinib/farmacología; Gefitinib/farmacología; Gefitinib/uso terapéutico; Neoplasias Pulmonares/metabolismo; Quinazolinas/farmacología; Quinazolinas/uso terapéutico; Receptores ErbB/metabolismo; Línea Celular Tumoral; Resistencia a Antineoplásicos; Mutación

Palabras clave

EGFR-TKI; ERK; HCC827-GR; HangAmDan-B1; afatinib; mTOR

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Integr Cancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google